PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Parabilis Medicines, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$25.35+2.60 (+11.43%)

Close on Oct 19, 2026

Market cap: $732.82M
P/E (TTM): –
Dividend yield: –

Parabilis Medicines, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Cash & Equivalents	28	50
Short-Term Investments	0	–
Cash & Short-Term Investments	28	50
Prepaid Expenses & Other	1.65	–
Total Current Assets	29	–
Property, Plant & Equipment	6.72	–
Gross Property, Plant & Equipment	20	–
Accumulated Depreciation	-13	–
Machinery & Equipment	0.70	–
Operating Lease Right-of-Use Assets	39	–
Total Assets	81	–
Accounts Payable	17	–
Accrued Expenses	19	–
Short-Term Debt	13	–
Current Portion of Long-Term Debt	13	–
Current Debt	13	–
Current Portion of Leases	7.17	–
Deferred Revenue (Current)	0	–
Total Current Liabilities	57	–
Long-Term Debt	0.60	–
Long-Term Leases	36	–
Operating Lease Liabilities	44	–
Total Liabilities	97	–
Total Debt	14	–
Preferred Stock	0	–
Common Stock	0	–
Additional Paid-In Capital	15	–
Retained Earnings	-542	–
Comprehensive Income & Other	0	–
Shareholders' Equity	-526	-384
Total Equity	-526	-384
Total Liabilities & Equity	81	–
Shares Outstanding(shares)	2.04	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 17.91
Debt to equity: 0.01
Debt to assets: 0.5%
Cash to current liabilities: 1729.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.70
Dividend yield: –